QA-09Updated 2026-05-19
TB-500 vs BPC-157: what is the difference?
Both are studied in tissue-repair research, but they act on different pathways. BPC-157 is a 15-AA sequence derived from gastric juice, studied for angiogenesis and gut healing. TB-500 (a fragment of Thymosin β4) is studied for actin regulation and cell migration.
BPC-157 and TB-500 are often discussed together in tissue-repair research because their published preclinical effects overlap. Their mechanisms, however, are distinct.
BPC-157
- A synthetic 15-amino-acid sequence derived from a protein in gastric juice.
- Studied in rodent models for angiogenesis, gut-mucosal repair, and tendon healing.
- Acts in part through VEGF and nitric oxide pathways.
TB-500 (Thymosin β-4 fragment)
- A synthetic fragment of the naturally occurring protein Thymosin β-4.
- Studied for its role in actin sequestration and cytoskeletal regulation, which influences cell migration.
- Research focus is on wound closure, cardiac tissue, and corneal repair.
The two are mechanistically complementary — researchers sometimes study them in parallel for that reason. Both are RUO; neither is FDA approved for human use. See the Healing pathway for the full set of tissue-repair compounds in our catalog.
// Related research pathways